Microbiotica entering clinic with live bacterial therapeutics
WEBAug 30, 2024 — Microbiotica Ltd. is poised to advance two of its microbiome-derived products into the clinic after securing regulatory approval and fresh finance. The first live bacterial therapeutic, MB-097, will be tested in combination with Keytruda (pembrolizumab) in patients with advanced melanoma who have not responded to treatment with immune checkpoint inhibitors.
University of Copenhagen discovers new PSD-95 inhibitors for ...
WEBJul 16, 2024 — University of Copenhagen has described cyclic peptides acting as postsynaptic density-95 (PSD-95) protein inhibitors reported to be useful for the treatment of neuropathic pain.
BioWorld MedTech: The Daily Medical Technology News Source
WEBSep 27, 2024 — Daily news and analysis of the medical technology industry. In-depth coverage of business, financing, regulation, science, innovation, device approvals, clinical trials and more.
China’s Ji Xing signs flurry of Asian deals to advance ... - BioWorld
WEBJan 12, 2024 — Shanghai-based Ji Xing Pharmaceuticals has signed a number of licensing deals over the last week for China rights to cardiovascular drugs to advance its pipeline and its global ambitions, partnering most recently with Tokyo-based TMS Co. Ltd. after the Chinese company acquired global rights for TMS-007 (also known as …
Australian researchers discover gene mutation that causes psoriasis
WEBMar 27, 2024 — Scientists from the Australian National University have discovered the gene mutation responsible for causing psoriasis, and the findings could lead to improved diagnosis and treatment for patients with psoriasis and psoriatic arthritis, a chronic inflammatory skin disease. “We were able to identify the gene that could be important in enabling this progression from a skin-only condition to a ...
Ideaya opening a new market with its first-in-class MAT2A inhibitor
WEBJul 8, 2024 — Ideaya Biosciences Inc. appears to be in the lead to develop a treatment for tumors with deletions in both copies of methylthioadenosine phosphorylase (MTAP). Despite the large market with an estimated annual incidence rate in the U.S. of approximately 75,000 patients, there are no FDA approved therapies for …
Biorchestra inks potential $861M deal to develop therapies for ...
WEBMar 29, 2023 — Biorchestra Co. Ltd. reached an exclusive research, option and licensing contract with a U.S.-based company to use its targeting technology platform to develop nucleic acid therapies to treat neurological disorders in a deal valued up to $861 million.
MSD acquires Curon’s CD3 x CD19 bispecific antibody for up to …
WEBAug 12, 2024 — Merck & Co. Inc. is acquiring Curon Biopharmaceutical Ltd.’s bispecific antibody CN-201 that targets CD3 and CD19 for B-cell associated diseases, for up to $1.3 billion. Under the terms of the deal, Merck (known as MSD outside of North America) through a subsidiary will acquire full global rights to …
BLX-3030, a selective CDK9 inhibitor for Myc-driven ... - BioWorld
WEBOct 18, 2023 — Researchers from Biolexis Therapeutics Inc. presented the development of a potent and highly selective CDK9 inhibitor, BLX-3030, and its analogues for the treatment of N-Myc and c-Myc-driven cancers.
Biohaven Therapeutics discovers new KCNQ2/3 activators
WEBBiohaven Therapeutics Ltd. has described potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators reported to be useful for the treatment of epilepsy, pain, dyskinesia, schizophrenia, anxiety disorders, stroke, Rett syndrome, substance abuse and dependence, among others.